Skip to main content
Log in

Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogendependent MXT mouse mammary cancers: Correlations between growth characteristics and EGF receptor content of tumors

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Female BDF mice bearing estrogen-dependent MXT mouse mammary cancers were treated for 4 weeks with a cytotoxic analog of luteinizing hormone-releasing hormone (LH-RH), T-98 (agonist [D-Lys6]LH-RH linked to glutaryl-2(hydroxymethyl)anthraquinone). The effects of T-98 were compared to those of equimolar amounts of the cytotoxic moiety 2-(hydroxymethyl)anthraquinone hemiglutarate (G-HMAQ) and carrier LH-RH agonist [D-Lys6]LH-RH. Both T-98 and [D-Lys6]LH-RH significantly inhibited the growth of MXT cancers, but G-HMAQ had only a minor non-significant effect. Cytotoxic analog T-98 and the carrier [D-Lys6]LH-RH had similar inhibitory hormonal activities on the pituitary-gonadal axis, but T-98 caused a larger reduction in tumor volume and decreased proliferation characteristics such as mitotic activity and AgNOR numbers in tumor cells to a greater extent than the carrier. Tumor inhibition by T-98, [D-Lys6]LH-RH, and ovariectomy was connected with a significant decrease in binding capacity of EGF receptors in tumor cell membranes. The concentration of EGF receptors remained high in tumors that continued to enlarge in spite of treatment and in all control untreated tumors, even those of small size. Thus, the changes in EGF receptors are likely to be the result of the therapy. Treatment with T-98 caused a greater reduction in the binding capacity of EGF receptors in tumors than [D-Lys6]LH-RH. This could explain the higher inhibitory effect of the cytotoxic analog on tumor growth. Since radiolabeled T-98 was shown to accumulate in MXT cancers 3 hours after a subcutaneous injection, this indicates that specific targeting might play a role in the antitumor effect exerted by this cytotoxic analog.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abbreviations

LH:

luteinizing hormone

LH-RH:

LH-releasing hormone

EGF:

epidermal growth factor

EGF-R:

EGF receptor

TGF:

transforming growth factor

NOR:

nucleolar organizing region

AgNOR:

argyrophilic NOR

G-HMAQ:

2(hydroxymethyl)anthraquinone-hemiglutarate

HPLC:

high performance liquid chromatography

TNF:

tumor necrosis factor

5-FU:

5-fluorouracil

PBS:

phosphate-buffered saline

References

  1. Sondik J: Breast cancer trends. Incidence, mortality, and survival. Cancer 74: 995–999, 1994

    PubMed  Google Scholar 

  2. Santen RJ, Manni A, Harvey H, Redmond C: Endocrine treatment of breast cancer in women. Endocr Rev 11: 221–265, 1990

    PubMed  Google Scholar 

  3. Robinson SP, Jordan VC: Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 49: 1758–1762, 1989

    PubMed  Google Scholar 

  4. Noguchi M, Tajiri K, Taniya T, Kumaki T, Ashikari A, Miyazaki I: Influence of hormones on proliferation of ER-positive cells and ER-negative cells of human breast cancer (MCF-7). Oncology 47: 19–24, 1990

    PubMed  Google Scholar 

  5. Fendl C, Zimniski SJ: Role of tamoxifen in the induction of hormone-independent rat mammary tumors. Cancer Res 52: 235–237, 1992

    PubMed  Google Scholar 

  6. Schally AV, Comaru-Schally AM, Hollander V: Hypothalamic and other peptide hormones. Chapter XVII-3. In: Holland JF, Frei E, Bast EC, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer Medicine, 3rd edition. Philadelphia PA, Lea & Febiger, 1993, pp 827–840

    Google Scholar 

  7. Emons G, Schally AV: The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Human Reprod 9: 1364–1379, 1994

    Google Scholar 

  8. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM: Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 131: 231–233, 1985

    Google Scholar 

  9. Foekens JA, Klijn JGM: Direct antitumor effects of LH-RH analogs. Rec Results Cancer Res 124: 7–17, 1992

    Google Scholar 

  10. Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV: Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res Treat 21: 181–192, 1992

    PubMed  Google Scholar 

  11. Eidne KA, Flanagan CA, Harris NS, Millar RP: Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64: 425–432, 1987

    PubMed  Google Scholar 

  12. Fekete M, Wittliff JL, Schally AV: Characteristics and distribution of receptors for [D-Trp6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3: 137–147, 1989

    PubMed  Google Scholar 

  13. Srkalovic G, Szende B, Redding TW, Groot K, Schally AV: Receptors for D-Trp-6-luteinizing hormone-releasing hormone, somatostatin and insulin-like growth factor I in MXT mouse mammary carcinoma. Proc Soc Exp Biol Med 192: 209–218, 1989

    PubMed  Google Scholar 

  14. Vincze B, Palyi I, Daubner D, Kremmer T, Szamel I, Bodrogi I, Sugar J, Seprodi J, Mezo I, Taplan Iet al.: Influence of luteinizing hormone-releasing hormone agonists on human mammary carcinoma cell lines and their xenografts. J Steroid Biochem Mol Biol 38: 119–126, 1991

    PubMed  Google Scholar 

  15. Carbone PP, Nixon DW, Fennelly J, Greenberg E, Henderson IC, Hortobagyi G, Kennedy BJ, Trainin N, Scanlon EF: Adjuvant systemic therapy. Cancer 65: 2108–2109, 1990

    PubMed  Google Scholar 

  16. Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, Cummings FI: Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. Cancer 65: 200–206, 1990

    PubMed  Google Scholar 

  17. Bonadonna G: From adjuvant to neo-adjuvant chemotherapy in high-risk breast cancer: the experience of the Milan Cancer Institute. Steiner Award Lecture 1992. Int J Cancer 55: 1–4, 1993

    PubMed  Google Scholar 

  18. Schally AV: Hypothalamic hormones: from neuroendocrinology to cancer therapy. Anti-Cancer Drugs 5: 115–130, 1994

    PubMed  Google Scholar 

  19. Bajusz S, Janaky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G, Redding TW, Schally AV: Highly potent analogues of luteinizing hormone-releasing hormone containing Dphenylalanine nitrogen mustard in position 6. Proc Natl Acad Sci USA 86: 6318–6322, 1989

    PubMed  Google Scholar 

  20. Bajusz S, Janaky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G, Redding TW, Schally AV: Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 86: 6313–6317, 1989

    PubMed  Google Scholar 

  21. Janaky T, Juhasz A, Bajusz S, Csernus V, Srkalovic G, Bokser L, Redding TW, Nagy A, Schally AV: Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups. Proc Natl Acad Sci USA 89: 972–976, 1992

    PubMed  Google Scholar 

  22. Szepeshazi K, Schally AV, Juhasz A, Nagy A, Janaky T: Effect of LH-RH analogs containing cytotoxic radicals on growth of estrogen independent MXT mouse mammary carcinomain vivo. Anti-Cancer Drugs 3: 109–116, 1992

    PubMed  Google Scholar 

  23. Pinski J, Schally AV, Yano T, Szepeshazi K, Halmos G, Groot K, Comaru-Schally AM, Radulovic S, Nagy A: Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals. Prostate 23: 165–178, 1993

    PubMed  Google Scholar 

  24. Szoke B, Horvath J, Halmos G, Rekasi Z, Groot K, Nagy A, Schally AV: LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cellsin vitro. Peptides 15: 359–366, 1994

    PubMed  Google Scholar 

  25. Szepeshazi K, Schally AV, Halmos G, Groot K, Radulovic S: Antagonist of bombesin/GRP releasing peptide inhibits growth of estrogen dependent and independent MXT mammary cancer in mice. J Natl Cancer Inst 84: 1915–1922, 1992

    PubMed  Google Scholar 

  26. Halmos G, Wittliff JL, Schally AV: Characterization of bombesin/GRP receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 53: 280–287, 1995

    Google Scholar 

  27. Munson PJ, Rodbard S: LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107: 220–239, 1980

    PubMed  Google Scholar 

  28. Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM, Schally AV: Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LHRH. Breast Cancer Res Treat 21: 35–45, 1992

    PubMed  Google Scholar 

  29. Mullen P, Scott WN, Miller WR: Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. Br J Cancer 63: 930–932, 1991

    PubMed  Google Scholar 

  30. Milovanovic SR, Monje E, Szepeshazi K, Radulovic S, Schally A: Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing hormone-releasing hormone in MXT mouse mammary carcinoma. J Cancer Res Clin Oncol 119: 273–278, 1993

    PubMed  Google Scholar 

  31. Sainsbury JR, Farndon JR, Sherbet GVet al.: Epidermalgrowth-factor receptors and oestrogen receptors in human breast cancer. Lancet 1: 364–366, 1985

    PubMed  Google Scholar 

  32. Formento JL, Francoual M, Formento P, Etienne MC, Fischel JL, Namer M, Frenay M, François E, Milano G: Epidermal growth factor receptor assay: Validation of a single point method and application to breast cancer. Breast Cancer Res Treat 17: 211–219, 1990

    Google Scholar 

  33. Osborne CK: Regulation of breast cancer growth by steroid hormones and growth factors: Clinical implications. Cancer Bull 45: 483–488, 1993

    Google Scholar 

  34. Lewis S, Locker A, Todd JH, Bell JA, Nicholson R, Elston CW, Blamey RW, Ellis IO: Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 43: 970–976, 1990

    Google Scholar 

  35. Gasparini G, Bevilacqua P, Pozza F, Meli S, Boracchi P, Marubini E, Sainsbury JRC: Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer 66: 970–976, 1992

    PubMed  Google Scholar 

  36. Naor Z: Signal transduction mechanisms of Ca2+ mobilizing hormones: The case of gonadotropin-releasing hormone. Endocrine Rev 11: 326–353, 1990

    Google Scholar 

  37. Ewing TM, Murphy LJ, Ng ML, Pang GYN, Lee CSL, Watts KW, Sutherland RL: Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int J Cancer 44: 744–752, 1989

    PubMed  Google Scholar 

  38. Gregory H, Thomas CE, Willshire IR, Yorg JA, Anderson H, Baildam A, Howell A. Epidermal and transforming growth factor α in patients with breast tumors. Br J Cancer 59: 605–609, 1989

    PubMed  Google Scholar 

  39. Guazzoni L, Perego P, Banfi P, Zunino F: Modulation of epidermal growth factor receptor tyrosine phosphorylation by tumor necrosis factor. Cancer Lett 57: 103–108, 1991

    PubMed  Google Scholar 

  40. Yano T, Pinski J, Szepeshazi K, Halmos G, Radulovic S, Groot K, Schally AV: Inhibitory effect of bombesin/gastrin releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Cancer 73: 1229–1238, 1994

    PubMed  Google Scholar 

  41. Shirahige Y, Cai R-Z, Szepeshazi K, Halmos G, Pinski J, Groot K, Schally AV: Inhibitory effect of bombesin/gastrinreleasin peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice. Biomed & Pharmacother 48: 465–472, 1994

    Google Scholar 

  42. Hanauske A-R, Osborne CK, Chamness GC, Clark GM, Forseth BJ, Buchok JB, Arteaga CL, von Hoff DD: Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. Eur J Cancer Clin Oncol 23: 545–551, 1987

    PubMed  Google Scholar 

  43. Miller WR: Prognostic factors in breast cancer. Br J Cancer 66: 775–776, 1992

    PubMed  Google Scholar 

  44. Derenzini M, Trere D: Importance of interphase nucleolar organizer regions in tumor pathology. Virchows Arch B Cell Pathol 61: 1–8, 1991

    Google Scholar 

  45. Szepeshazi K, Korkut E, Schally AV: Decrease in AgNOR number in Dunning R3327 prostate cancer after treatment with LH-RH agonist and antagonist. Am J Pathol 138: 1273–1277, 1991

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Szepeshazi, K., Schally, A.V., Halmos, G. et al. Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogendependent MXT mouse mammary cancers: Correlations between growth characteristics and EGF receptor content of tumors. Breast Cancer Res Tr 40, 129–139 (1996). https://doi.org/10.1007/BF01806208

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806208

Key words

Navigation